Notably, reductions in NfL levels have been associated with slowed disease progression in ALS patients receiving the antisense oligonucleotide therapy Tofersen for SOD1-driven ALS [47, 48], making our findings particularly relevant in the context of senolytic treatment. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.